LBRX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
62.5M
+15.9%
53.9M
+143.9%
22.1M
+59.4%
13.9M
+164.4%
5.2M
R&D
51.5M
+16.7%
44.1M
+201.4%
14.6M
+72.6%
8.5M
+250.7%
2.4M
SG&A
11.0M
+12.4%
9.8M
+31.0%
7.5M
+38.5%
5.4M
+90.6%
2.8M
Operating Income
-62498000
-15.9%
-53915000
-143.9%
-22104000
-59.4%
-13870000
-164.4%
-5246000
EBITDA
-62374000
-15.9%
-53818000
-144.4%
-22022000
-59.8%
-13785000
-166.9%
-5165000
Net Income
-59066000
-14.5%
-51603000
-170.8%
-19054000
-66.1%
-11472000
-222.6%
-3556000
EPS (Basic)
$-1.79
-4.7%
$-1.71
-155.2%
$-0.67
-48.9%
$-0.45
+26.2%
$-0.61
EPS (Diluted)
$-1.79
-4.7%
$-1.71
-155.2%
$-0.67
-48.9%
$-0.45
+26.2%
$-0.61
Shares (Diluted)
33.1M
+9.8%
30.1M
+6.7%
28.2M
+10.1%
25.7M
+341.8%
5.8M
LB Pharmaceuticals (LBRX) — Financials